Unknown

Dataset Information

0

Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.


ABSTRACT: Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1? release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1? release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07?mg/kg. The P2X7 antagonist (3?mg/kg, oral) blocked Bz-ATP-induced brain IL-1? release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30?mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8?mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG-induced depression, JNJ-55308942 dosed orally (30?mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation. Finally, in a rat model of chronic stress induced sucrose intake deficit, JNJ-55308942 reversed the deficit with concurrent high P2X7 brain occupancy as measured by autoradiography. This body of data demonstrates that JNJ-55308942 is a potent P2X7 antagonist, engages the target in brain, modulates IL-1? release and microglial activation leading to efficacy in two models of anhedonia in rodents.

SUBMITTER: Bhattacharya A 

PROVIDER: S-EPMC6224414 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.

Bhattacharya Anindya A   Lord Brian B   Grigoleit Jan-Sebastian JS   He Yingbo Y   Fraser Ian I   Campbell Shannon N SN   Taylor Natalie N   Aluisio Leah L   O'Connor Jason C JC   Papp Mariusz M   Chrovian Christa C   Carruthers Nicholas N   Lovenberg Timothy W TW   Letavic Michael A MA  

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20180709 13


Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blo  ...[more]

Similar Datasets

| S-EPMC5880301 | biostudies-literature
| S-EPMC6014699 | biostudies-literature
| S-EPMC3755531 | biostudies-literature
2021-08-10 | GSE135110 | GEO
| S-EPMC8999829 | biostudies-literature
| S-EPMC9815700 | biostudies-literature
| S-EPMC3792000 | biostudies-literature
| S-EPMC3077709 | biostudies-literature
2004-05-08 | GSE1368 | GEO
| S-EPMC10895799 | biostudies-literature